Cognitive complaints after breast cancer treatments: Examining the relationship with neuropsychological test performance

Journal of the National Cancer Institute

Volumn 105, Issue 11, 2013, Pages 791-801

  Ganz, Patricia A ^a,b,c   Kwan, Lorna ^b,c   Castellon, Steven A ^c,d,f   Oppenheim, Amy ^b,c   Bower, Julienne E ^a,c,d,e   Silverman, Daniel H S ^a   Cole, Steve W ^a,e   Irwin, Michael R ^a,c,d,e   Ancoli Israel, Sonia ^g   Belin, Thomas R ^a  

^a Department of Health Policy and Management ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEMORY DISORDER; MULTIMODALITY CANCER THERAPY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RADIATION INJURY; SELF REPORT; TASK PERFORMANCE; VERBAL MEMORY; VISUAL MEMORY;

ADULT; ANTINEOPLASTIC AGENTS; ANXIETY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; DEPRESSION; FATIGUE; FEMALE; HIGHER NERVOUS ACTIVITY; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MEMORY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; SELF REPORT;

EID: 84878847958     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt073     Document Type: Article

References (52)

1. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Wiliston Park). 2000; 14(1):75-79.
2. Butler RW, Hill JM, Steinherz PG, Meyers PA, Finlay JL. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol. 1994; 12(12):2621-2629. (Pubitemid 24379648)
3. Meyers CA. How chemotherapy damages the central nervous system. J Biol. 2008; 7(4):11.
4. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of noncentral nervous system cancer and cancer therapy. Neuropsychol Rev. 2008; 18(2):121-131.
5. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20(2):485-493. (Pubitemid 34072533)
6. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85(3):640-650. (Pubitemid 29075285)
7. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001; 51(2):159-165. (Pubitemid 32435496)
8. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative chemotherapy for breast carcinoma. Cancer. 1999; 85(3):640-650. (Pubitemid 29075285)
9. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90(3):210-218. (Pubitemid 28114539)
10. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13(9):1387-1397.
11. Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FS. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005; 94:53-61. (Pubitemid 41416942)
12. Wefel JS, Lenzi R, Therlault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer. 2004; 100(11):2292-2299.
13. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18(14):2695-2701. (Pubitemid 30463551)
14. Castellon SA, Ganz PA, Bower JE, Petersen LA, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26(7):955-969. (Pubitemid 39577316)
15. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004; 13(1):61-66. (Pubitemid 38139358)
16. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94:828-834.
17. Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst. 1998; 90(3):182-183. (Pubitemid 28114536)
18. Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578-3587.
19. McDonald B, Conroy S, Ahles T, West J, Saykin A. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010; 123(3):819-828.
20. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012; 30(20):2500-2508.
21. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274-281.
22. Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011; 68(11):1447-1453.
23. Pullens MJJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology. 2010; 19(11):1127-1138.
24. Ganz PA, Bower JE, Kwan L,.et al. Does tumor necrosis factor-alpha (TNF) play a role in post-chemotherapy cerebral dysfunction?. Brain Behav Immun. 2013; 30(suppl):S99-S108.
25. Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol. 2011; 29(9):1101-1109.
26. Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011; 29(26):3517-3522.
27. Beck AT, Steer RA, Brown GK. BDI-II; Beck Depression Inventory. 2nd ed. Boston, MA: Harcourt Brace Inc, 1996.
28. Chelune CJ, Heaton RK, Lehman RAW. Neuropsychological and personality correlates of patients' complaints of disability. In: Goldstein G, Tarter RE, eds. Advances in Clinical Neuropsychology, Volume 3. New York, NY: Plenum Press; 1986:95-126.
29. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15:422-430. (Pubitemid 43826855)
30. Bender CM, Pacella ML, Sereika SM, et al. What do perceived cognitive problems reflect? J Support Oncol. 2008; 6:238-242. (Pubitemid 351836613)
31. Liu L, Rissling M, Neikrug A, et al. Fatigue and circadian activity rhythms in breast cancer patients before and after chemotherapy: a controlled study. Fatigue. 2012;1(1-2):12-26.
32. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004; 27(1):14-23. (Pubitemid 38050244)
33. Tulsky DS, Price LR. The joint WAIS-III and WMS-III factor structure: development and cross-validation of a six-factor model of cognitive functioning. Psychol Assess. 2003; 15(2):149-162. (Pubitemid 36750523)
34. Berent-Spillson A, Persad CC, Love T, et al. Early menopausal hormone use influences brain regions used for visual working memory. Menopause. 2010; 17(4):692-699.
35. Ryan J, Carrie I, Scali J, Ritchie K, Ancelin ML. Life-time estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology. 2009; 34(2):287-298.
36. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004; 96(5):376-387. (Pubitemid 38351299)
37. Henderson VW, Greicius MD. Functional magnetic resonance imaging and estrogen effects on the brain: cautious interpretation of a BOLD finding. Menopause. 2010; 17(4):669-671.
38. Greendale GA, Wight RG, Huang MH, et al. Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation. Am J Epidemiol. 2010; 171(11):1214-1224.
39. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin N Am. 2011; 38(3):519-535.
40. Boulware M, Kent B, Frick K. The impact of age-related ovarian hormone loss on cognitive and neural function. In: Pardon MC, Bondi MW, eds. Behavioral Neurobiology of Aging. 10th ed. Berlin, Germany: Springer; 2012:165-184.
41. Maki PM, Dennerstein L, Clark M, et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. Brain Res. 2011; 1379(0):232-243.
42. Schaafsma M, Homewood J, Taylor A. Subjective cognitive complaints at menopause associated with declines in performance of verbal memory and attentional processes. Climacteric. 2010; 13(1):84-98.
43. Weber MT, Mapstone M, Staskiewicz J, Maki PM. Reconciling subjective memory complaints with objective memory performance in the menopausal transition. Menopause. 2012; 19(7):735-741.
44. Dumas JA, Kutz AM, McDonald BC, et al. Increased working memoryrelated brain activity in middle-aged women with-cognitive complaints. Neurobiol Aging. 2013;34(4):1145-1147.
45. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7(3):192-201.
46. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008; 8(11):887-899.
47. Ahles TA. Brain vulnerability to chemotherapy toxicities. Psychooncology. 2012; 21(11):1141-1148.
48. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors [published online ahead of print]. Brain Behav Immun. 2013; 30(suppl):S109-S116.
49. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008; 26(6):971-982. (Pubitemid 351409339)
50. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013; 30(suppl):S48-S57.
51. Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006; 67(5):834-842. (Pubitemid 44394199)
52. Ganz PA. Doctor, Will the treatment you are recommending cause chemobrain? J Clin Oncol. 2012; 30(3):229-231.